Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Non-Active Secondary Progressive Multiple Sclerosis”

10 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 10 of 10 results

Not applicableStudy completedNCT05376579
What this trial is testing

Impact of Mayzent on aSPMS Patients in a Long-term NIS in Italy

Who this might be right for
Active Secondary Progressive Multiple Sclerosis
Novartis Pharmaceuticals 134
Not applicableAvailableNCT06802328
What this trial is testing

Intermediate-Size Patient Population Expanded Access: Foralumab in Non-Active Secondary Progressive MS Patients

Who this might be right for
Non-Active Secondary Progressive Multiple Sclerosis
Tiziana Life Sciences LTD
Large-scale testing (Phase 3)Active Not RecruitingNCT05441488
What this trial is testing

Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple Sclerosis

Who this might be right for
Progressive Multiple Sclerosis
AB Science 800
Large-scale testing (Phase 3)Active Not RecruitingNCT04688788
What this trial is testing

Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis

Who this might be right for
Relapsing Remitting Multiple SclerosisSecondary Progressive Multiple SclerosisPrimary Progressive Multiple Sclerosis
Rigshospitalet, Denmark 600
Early research (Phase 1)Temporarily pausedNCT06677710
What this trial is testing

IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis

Who this might be right for
Multiple SclerosisPrimary Progressive Multiple Sclerosis (PPMS)Secondary Progressive Multiple Sclerosis (SPMS)+8 more
Indapta Therapeutics, INC. 34
Large-scale testing (Phase 3)Looking for participantsNCT05961644
What this trial is testing

Cladribine vs Placebo for Non-active Progressive Multiple Sclerosis (CLASP-MS).

Who this might be right for
Multiple Sclerosis, Secondary ProgressiveMultiple Sclerosis
Institute of Psychiatry and Neurology, Warsaw 188
Large-scale testing (Phase 3)Looking for participantsNCT07299019
What this trial is testing

Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis

Who this might be right for
Secondary Progressive Multiple Sclerosis
Zenas BioPharma (USA), LLC 990
Testing effectiveness (Phase 2)Looking for participantsNCT06292923
What this trial is testing

Nasal Foralumab in Non-Active Secondary Progressive Multiple Sclerosis Patients

Who this might be right for
Secondary Progressive Multiple Sclerosis
Tiziana Life Sciences LTD 54
Testing effectiveness (Phase 2)Looking for participantsNCT06890923
What this trial is testing

Nasal Foralumab in Patients With Non-Active Secondary Progressive Multiple Sclerosis

Who this might be right for
Non-Active Secondary Progressive Multiple Sclerosis
Tiziana Life Sciences LTD 55
Not applicableEnded earlyNCT04895202
What this trial is testing

Swiss Study of the Impact of Mayzent on SPMS Patients in a Long-term Non-interventional Study

Who this might be right for
Secondary Progressive Multiple Sclerosis With Inflammatory Disease Activity
Novartis Pharmaceuticals 8